Moleculin to Announce Full Year Financials and Conference Call
HOUSTON — Moleculin Biotech, Inc. (Nasdaq: MBRX), a groundbreaking pharmaceutical company focused on developing solutions for challenging tumors and viral conditions, is set to disclose its financial results for the year ending December 31, 2024. The announcement will be made in a press release on Friday afternoon, and the management team will host a subsequent conference call and live audio webcast to engage with investors on Monday morning.
Details of the Financial Disclosure
The conference call is scheduled for 8:30 AM ET on March 24, 2025. Investors and interested parties can participate by calling (877) 407-0832 for domestic calls or (201) 689-8433 for international inquiries. During this session, executives will share insights regarding the company’s operational and financial performance over the past year.
Accessing the Live Webcast
For those unable to participate by phone, the live audio webcast will be available on the Events page of the Moleculin website. Additionally, this presentation will be archived for 90 days, allowing stakeholders the opportunity to review the information shared.
About Moleculin Biotech
Moleculin Biotech is currently in pivotal phases of clinical trials, dedicated to advancing therapies for challenging medical conditions. Their lead candidate, Annamycin, represents an innovative approach in the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases. This next-generation anthracycline aims to combat the issues of multidrug resistance and reduce cardiotoxicity often faced with traditional anthracyclines.
MIRACLE Trial: A Step Towards Approval
The company is embarking on the MIRACLE trial (Moleculin R/R AML Annamycin Clinical Evaluation), a critical Phase 3 study that focuses on Annamycin combined with cytarabine, known as AnnAraC. This trial follows a successful Phase 1B/2 study which provided encouraging results. With guidance from the FDA, Moleculin believes it has effectively minimized risks on the path toward regulatory approval.
Expanding Their Therapeutic Portfolio
In addition to Annamycin, Moleculin is also developing WP1066, a promising immune/transcription modulator designed to inhibit oncogenic factors like p-STAT3, all while bolstering the body’s immune response. This treatment strategy targets a variety of cancers, including aggressive brain tumors and pancreatic cancer. Moreover, the company is working on a series of antimetabolites, such as WP1122, aimed at addressing both viral infections and specific cancer indications.
Engagement with the Broader Medical Community
Moleculin recognizes the importance of collaboration and transparency in their efforts. Investors and professionals are encouraged to stay connected through their established channels, including the company's website and social media platforms. This engagement will not only showcase their advancements but also facilitate discussions with potential partners and stakeholders.
Investor Relations Information
For additional inquiries, interested parties can reach the Investor Relations team at JTC Team, LLC, with Jenene Thomas as the contact person. She can be reached at (908) 824-0775 or via email.
Frequently Asked Questions
1. What is Moleculin Biotech's main focus?
Moleculin Biotech specializes in developing treatments for hard-to-treat tumors and viral infections.
2. When will the financial results be announced?
The financial results for the year ending December 31, 2024, will be announced on March 21, 2025.
3. How can investors access the conference call?
Investors can dial (877) 407-0832 for domestic calls and (201) 689-8433 for international calls to participate in the conference call.
4. What is the MIRACLE trial?
The MIRACLE trial is a pivotal Phase 3 study evaluating the combination of Annamycin and cytarabine for treating acute myeloid leukemia.
5. How can I get more information about Moleculin?
More information about Moleculin’s research and programs can be found on their official website.
